ctDNA Is Moving Breast Cancer Genomics Beyond the Tissue Biopsy
Breast cancer still depends heavily on tissue sampling for molecular profiling, yet the limits of a single biopsy are hard to ignore in a disease marked by spatial and temporal heterogeneity. A core tumor specimen captures one moment in one place; it cannot fully represent the shifting genomic architecture that emerges as disease evolves under treatment pressure. Circulating tumor DNA offers a different approach. As a tumor-derived fraction of cell-free DNA in the bloodstream, it can carry genomic information that reflects current disease biology rather than a static snapshot from the original lesion.
This review places ctDNA at the center of a broader precision oncology shift in breast cancer. The most immediate appeal is practical: a blood draw is less invasive than repeat tissue biopsy, easier to repeat over time, and better suited to serial monitoring during therapy. In advanced disease, where treatment selections often depend on newly acquired resistance alterations, that real-time readout can have direct consequences for drug choice. In early-stage disease, the same technology is being pushed toward detection of microscopic residual disease, a use case that could change follow-up strategies if the assays prove reliable enough for routine care.
One sentence captures the tension in the field: clinical promise is outpacing routine implementation.
Actionable Alterations Are Detectable, but the Assay Matters
The review identifies several analytical platforms already in clinical and translational use, including digital PCR, BEAMing, and next-generation sequencing. These methods are not interchangeable. Each differs in sensitivity, breadth of genomic coverage, and ability to detect low-frequency variants, which becomes crucial when the amount of ctDNA in circulation is small. The review specifically notes detection of alterations in PIK3CA, ESR1, TP53, ERBB2, AKT1, and BRCA1/2, a gene set that spans endocrine resistance, oncogenic signaling, DNA repair defects, and HER2-related biology.
Those alterations matter because they are not abstract biomarkers. ESR1 mutations can emerge under endocrine pressure and help explain resistance to hormone-based therapy. PIK3CA and AKT1 alterations point toward pathway activation that may support targeted therapeutic selection. BRCA1/2 findings can be clinically relevant in the broader context of DNA repair deficiency. ERBB2 alterations can signal a biologic shift with treatment implications even when tumor tissue did not initially reveal that pattern. ctDNA therefore functions not simply as a monitoring tool, but as a genomic surveillance strategy that may catch therapeutic escape before it becomes obvious on imaging or symptoms.
Minimal Residual Disease and Resistance Monitoring Drive the Strongest Rationale
The strongest current applications sit in three areas: minimal residual disease detection, treatment response monitoring, and emerging resistance surveillance. After local therapy or systemic treatment, ctDNA can theoretically reveal whether malignant cells remain below the threshold of radiographic detection. In the metastatic setting, serial assays may track whether a tumor is shrinking molecularly, stabilizing, or re-expanding despite ongoing therapy. When resistant clones appear, ctDNA may identify the genomic changes responsible and support a pivot to another regimen.
That biologic logic is compelling because ctDNA is dynamic by design. Tumors shed DNA into the circulation, and as clonal populations expand or contract under treatment, the circulating profile can shift with them. A tissue biopsy performed months earlier cannot capture that evolution. For breast cancer, where therapeutic sequencing often depends on the emergence of a specific resistance mechanism, the ability to follow the tumor genome over time is the central argument for liquid biopsy.
Early Detection Remains a Narrower and More Difficult Frontier
The review is cautious about broader uses such as early cancer detection and population screening. In early-stage disease, ctDNA abundance is low, which makes detection technically difficult and raises concerns about false negatives. Low tumor burden reduces signal, while analytic noise becomes more consequential. These are not minor engineering issues; they determine whether a test can be trusted in real-world care.
Artificial intelligence-assisted decision-making is also described as investigational. The concept is appealing, especially in an environment where ctDNA datasets are complex and longitudinal, but the review does not present this as ready for routine use. Clinical adoption will require more than computational sophistication. It will require reproducible assays, clear thresholds for action, and prospective evidence showing that decisions based on ctDNA actually improve outcomes rather than simply generate more data.
A second blunt reality follows from the biology: early-stage disease often sheds too little ctDNA to support confident inference.
Standardization and Cost Will Decide How Fast ctDNA Moves Into Practice
Analytical variability remains one of the biggest barriers to routine implementation. Different platforms can yield different levels of sensitivity and specificity, and without standardization across laboratories, comparing results becomes difficult. The review also points to limited assay harmonization and cost considerations as constraints on wider adoption. These limitations matter because precision oncology depends on consistency. A biomarker that changes meaning from one platform to another is hard to embed in treatment algorithms.
Prospective multicenter validation is therefore essential. So is the development of evidence-based guidelines that specify when ctDNA should be ordered, how results should be interpreted, and which clinical scenarios justify action. At present, the technology is best supported where the biology is most favorable: advanced breast cancer, response assessment, resistance detection, and molecular residual disease evaluation. Those are the settings where tumor shedding is more likely to be measurable and where genomic change is most clinically consequential.
Precision Breast Cancer Care Now Depends on Better Evidence
The review frames ctDNA as a major step toward noninvasive genomic profiling, but not a finished solution. It offers a real route to capture tumor heterogeneity, follow disease over time, and identify alterations that can change treatment selection. It also exposes the gulf between technical feasibility and clinical readiness. Sensitive platforms can already detect actionable mutations, yet the field still lacks the standardization, validation, and guideline structure needed for universal use.
For now, ctDNA looks most credible as an adjunct to tissue, not a replacement. Tissue biopsy remains essential for initial diagnosis and many molecular decisions, while liquid biopsy may increasingly fill the gaps between tissue samples, especially when tumors evolve under therapy. The next stage will depend on prospective multicenter data, clearer testing protocols, and proof that ctDNA-guided decisions improve care in breast cancer rather than simply refine the description of it.